CRISTHIAM MAURICIO ROJAS HERNANDEZ
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 9 | 2023 | 335 | 3.300 |
Why?
|
| Anticoagulants | 7 | 2023 | 787 | 1.890 |
Why?
|
| Heparin, Low-Molecular-Weight | 3 | 2017 | 66 | 1.310 |
Why?
|
| Intracranial Hemorrhages | 2 | 2017 | 121 | 1.080 |
Why?
|
| Anemia, Hemolytic | 1 | 2022 | 53 | 0.850 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2022 | 106 | 0.830 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 110 | 0.810 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 329 | 0.650 |
Why?
|
| Vena Cava Filters | 1 | 2018 | 88 | 0.610 |
Why?
|
| Anemia, Pernicious | 1 | 2015 | 11 | 0.520 |
Why?
|
| Autoimmune Diseases | 2 | 2015 | 402 | 0.520 |
Why?
|
| Pancytopenia | 1 | 2015 | 120 | 0.510 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 257 | 0.490 |
Why?
|
| Neoplasms | 5 | 2023 | 15193 | 0.440 |
Why?
|
| Primary Myelofibrosis | 1 | 2015 | 831 | 0.300 |
Why?
|
| Administration, Oral | 3 | 2023 | 1544 | 0.270 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2023 | 9 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 6915 | 0.220 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 2979 | 0.210 |
Why?
|
| Plasma Exchange | 1 | 2022 | 117 | 0.200 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 87 | 0.170 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2019 | 68 | 0.170 |
Why?
|
| Neutropenia | 1 | 2023 | 968 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 600 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 276 | 0.150 |
Why?
|
| Humans | 15 | 2023 | 261506 | 0.150 |
Why?
|
| Hemorrhage | 2 | 2023 | 712 | 0.150 |
Why?
|
| Vitamin K | 1 | 2017 | 54 | 0.140 |
Why?
|
| Thrombosis | 1 | 2023 | 781 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 882 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 806 | 0.140 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 2843 | 0.130 |
Why?
|
| Risk Factors | 3 | 2023 | 17523 | 0.130 |
Why?
|
| Methylmalonic Acid | 1 | 2015 | 15 | 0.130 |
Why?
|
| Vitamin B 12 | 1 | 2015 | 73 | 0.130 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2015 | 53 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 1215 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.110 |
Why?
|
| Prevalence | 1 | 2019 | 3260 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 2138 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 252 | 0.100 |
Why?
|
| Aged | 4 | 2019 | 70117 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2015 | 558 | 0.090 |
Why?
|
| Lymphoma | 1 | 2019 | 1467 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 4744 | 0.090 |
Why?
|
| Leukemia | 1 | 2019 | 1635 | 0.090 |
Why?
|
| Sex Factors | 1 | 2015 | 2139 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2023 | 12873 | 0.080 |
Why?
|
| Recurrence | 1 | 2016 | 4758 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2015 | 2358 | 0.080 |
Why?
|
| Biopsy | 1 | 2015 | 3443 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 9244 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8865 | 0.070 |
Why?
|
| Middle Aged | 3 | 2019 | 86204 | 0.070 |
Why?
|
| Female | 4 | 2019 | 141928 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 10001 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 7548 | 0.060 |
Why?
|
| Algorithms | 1 | 2015 | 3890 | 0.060 |
Why?
|
| Rivaroxaban | 1 | 2023 | 59 | 0.060 |
Why?
|
| Male | 3 | 2019 | 123000 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 37905 | 0.050 |
Why?
|
| United States | 1 | 2019 | 15433 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2023 | 369 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 4849 | 0.040 |
Why?
|
| Adult | 2 | 2023 | 77950 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 1183 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2015 | 32848 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 2864 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 6682 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2023 | 6869 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6009 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10035 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 15862 | 0.010 |
Why?
|